Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 15, 2013. The report details a specific share repurchase transaction executed under shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on share capital movements.
- Shares Purchased: 314,497 Ordinary Shares of 25 pence each.
- Purchase Date: November 15, 2013.
- Price Range: Highest price paid was 1,622.00 pence per share; lowest price paid was 1,606.00 pence per share.
- Treasury Holdings (Settled): 508,442,412 shares (9.47% of total issued share capital).
- Treasury Holdings (Including Unsettled): 509,932,909 shares (10.49% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,862,711,765 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 314,497 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.49% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a compliance disclosure confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (508,442,412 settled) against the company's latest annual report.
- Confirm the total issued share capital excluding Treasury shares (4,862,711,765) for voting rights calculations.
- Check the price paid per share (1,606.00 to 1,622.00 pence) against market trading data for November 15, 2013.
- Review the remaining authorization for share buybacks under the mandate granted on May 1, 2013.